查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1798926

異噁唑啉的全球市場

Isoxazoline
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 271 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球異噁唑啉市場規模將達 77 億美元

全球異噁唑啉市場規模預計在2024年為50億美元，到2030年將達到77億美元，在分析期間（2024-2030年）的複合年成長率為7.7%。氟拉那（Flulanar）是本報告分析的細分市場之一，預計其複合年成長率為5.3%，到分析期結束時規模將達到26億美元。阿福拉那（Afoxolanar）細分市場在分析期間的複合年成長率預計為9.3%。

美國市場規模估計為 14 億美元，中國市場預計複合年成長率為 11.6%

預計到2024年，美國異噁唑啉市場規模將達14億美元。作為世界第二大經濟體，中國市場規模預計到2030年將達到16億美元，在2024-2030年的分析期間內，複合年成長率為11.6%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為4.0%和7.3%。在歐洲，預計德國市場的複合年成長率為5.0%。

全球異噁唑啉市場－主要趨勢與促進因素摘要

為什麼異噁唑啉在動物用藥品和殺寄生蟲劑開發中脫穎而出？

異噁唑啉是一類廣泛用於獸醫學的化合物，用於治療和預防犬貓體外寄生蟲，例如跳蚤和蜱蟲。異噁唑啉類分子作為昆蟲GABA和麩胺酸門控氯離子通道的選擇性拮抗劑，能夠干擾寄生蟲的中樞神經系統，而不會對哺乳動物產生影響。其特異性高、作用時間長、全身有效，使其成為首選的局部和口服抗寄生蟲藥物。

這些化合物在解決老款抗寄生蟲藥物的抗藥性問題方面尤其有效。獸藥公司持續將異噁唑啉衍生物製成咀嚼錠、點滴液和注射劑，為飼主提供便利，並提高治療順從性。由於它們能夠單劑量持續控制多種寄生蟲，因此受到臨床醫生和寵物護理專業人士的青睞。

哪些創新和監管部門的核准正在推動產品開發？

目前正在合成新的異噁唑啉衍生物，以拓寬活性頻譜、最大程度降低副作用，並解決不同年齡層和品種的安全性問題。異噁唑啉與心臟預防劑、殺線蟲劑和其他昆蟲生長調節劑的聯合治療正在開發中，以擴大寄生蟲覆蓋範圍。此類聯合療法旨在簡化預防方案並提高市場接受度。

全球各市場監管部門的核准增強了異噁唑啉類產品的商業性影響力。嚴格的品質和安全評估已認可這些化合物良好的風險-效益特性。上市後監測和現場數據持續支持其在長期獸用中的有效性和安全性。此外，伴侶動物照護領域投資的不斷增加也鼓勵製藥公司推出新的品牌藥和非專利藥。

市場需求在哪裡成長以及主要最終用戶是誰？

伴侶動物保健產品的需求正在成長，尤其是在飼養易受跳蚤侵擾的室內寵物的家庭，以及蜱蟲肆虐的地區。寵物飼主正在尋找可靠、長效且每年只需少量劑量的預防產品。獸醫和動物醫院是主要的處方提供者，透過零售藥局和動物醫院分銷的管道也不斷擴大。

北美和歐洲是成熟的市場，得益於較高的寵物擁有率、常規預防保健措施以及清晰的監管。亞太地區和拉丁美洲由於人們意識的提高和獸醫基礎設施的改善，寵物護理的採用率正在上升。在新興的寵物照護產業，處方級抗寄生蟲藥物的可近性逐漸提高，進一步推動了需求。

推動異噁唑啉市場成長的因素是什麼？

異噁唑啉市場的成長受到多種因素的推動，包括寵物擁有量的增加、對長效有效體外寄生蟲控制的需求不斷成長，以及動物用藥品的不斷創新。藥物配方技術的進步、安全性的提高以及對多種寄生蟲的廣泛療效，正在提升此類產品的吸引力。

伴侶動物診所、寵物照護零售商和線上動物藥局平台的終端使用機會不斷擴大，提高了產品的可近性。針對多種動物的組合產品的開發和監管核准進一步提高了其使用量。隨著寄生蟲抗藥性和寵物醫療保健需求的不斷成長，異噁唑啉類殺寄生蟲劑仍然是現代獸醫預防保健的重要組成部分。

部分

化合物（氟拉拉納、阿福拉納、薩羅拉納、洛蒂拉納）；寵物類型（貓、狗）

受訪公司範例

  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • Hitek Animal Health
  • KRKA dd
  • Merck Animal Health（MSD AH）
  • Norbrook Laboratories
  • Orion Corporation
  • Ourofino Saude Animal
  • PetIQ, Inc.
  • Phibro Animal Health Corporation
  • Sogeval Laboratories
  • Syngene International Ltd.
  • Vetoquinol SA
  • Virbac
  • Zoetis Inc.

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global 特定產業產業SLM 的典型規範，而是建立了一個從世界各地專家收集的內容庫，包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP38973

Global Isoxazoline Market to Reach US$7.7 Billion by 2030

The global market for Isoxazoline estimated at US$5.0 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Fluralaner, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Afoxolaner segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.6% CAGR

The Isoxazoline market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Isoxazoline Market - Key Trends & Drivers Summarized

Why Is Isoxazoline Gaining Ground in Animal Health and Parasiticide Development?

Isoxazoline refers to a chemical class of compounds widely used in veterinary medicine for the treatment and prevention of ectoparasites such as fleas and ticks in dogs and cats. Isoxazoline-based molecules function as selective antagonists of insect GABA- and glutamate-gated chloride channels, disrupting the central nervous system of parasites without affecting mammals. The high specificity, long duration of action, and systemic efficacy have made these compounds a preferred choice for both topical and oral parasiticide formulations.

These compounds are particularly effective in managing resistance issues that affect older antiparasitic agents. Veterinary pharmaceutical companies continue to formulate isoxazoline derivatives into chewable tablets, spot-on solutions, and injectable formats, offering convenience to pet owners and improving treatment compliance. Their utility in single-dose administration and persistent control across multiple parasite species has expanded their appeal among clinicians and pet care professionals.

What Innovations and Regulatory Approvals Are Advancing Product Development?

New derivatives of isoxazoline are being synthesized to extend spectrum of activity, minimize side effects, and address safety in different age groups and breeds. Combination therapies that pair isoxazolines with heartworm preventatives, nematocides, or other insect growth regulators are under development to provide broader parasitic coverage. These fixed-dose combinations aim to simplify preventive regimens and improve market adoption.

Regulatory approvals in various global markets have strengthened the commercial presence of isoxazoline-based products. With stringent quality and safety evaluations, these compounds have gained recognition for their favorable risk-benefit profile. Post-market surveillance and field data continue to support their efficacy and safety in long-term veterinary use. Further, rising investment in companion animal care is encouraging pharmaceutical companies to introduce new branded and generic isoxazoline formulations.

Where Is Market Demand Growing, and Who Are the Primary End-Users?

Demand is expanding in companion animal health, particularly among households with indoor pets susceptible to flea infestations and regions with endemic tick populations. Pet owners are seeking reliable, long-acting protection that requires fewer administrations per year. Veterinarians and animal hospitals are the primary prescribers, with growing distribution through retail pharmacies and veterinary clinics.

North America and Europe are mature markets, supported by high rates of pet ownership, routine preventive care practices, and regulatory clarity. Asia Pacific and Latin America are witnessing increasing adoption as awareness grows and veterinary infrastructure develops. Emerging pet care industries are gradually expanding access to prescription-grade parasiticides, further boosting demand.

What Is Driving Growth in the Isoxazoline Market?

Growth in the isoxazoline market is driven by several factors including rising pet ownership, increasing demand for long-acting and effective ectoparasite control, and expanding veterinary pharmaceutical innovation. Technological advances in drug formulation, improved safety profiles, and broader efficacy against multiple parasites are enhancing product attractiveness.

End-use expansion in companion animal clinics, pet care retail, and online veterinary pharmacy platforms is improving accessibility. Combination product development and regulatory approvals for diverse animal species are further strengthening usage. As parasite resistance and pet healthcare needs evolve, isoxazoline-based parasiticides are positioned to remain essential in modern veterinary preventive medicine.

SCOPE OF STUDY:

The report analyzes the Isoxazoline market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Chemical Compound (Fluralaner, Afoxolaner, Sarolaner, Lotilaner); Pet Type (Cat, Dog)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • Hitek Animal Health
  • KRKA d.d.
  • Merck Animal Health (MSD AH)
  • Norbrook Laboratories
  • Orion Corporation
  • Ourofino Saude Animal
  • PetIQ, Inc.
  • Phibro Animal Health Corporation
  • Sogeval Laboratories
  • Syngene International Ltd.
  • Vetoquinol S.A.
  • Virbac
  • Zoetis Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Isoxazoline - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Pet Ownership and Veterinary Care Spending Drive Demand for Isoxazoline-Based Ectoparasiticides
    • Expansion of Companion Animal Flea and Tick Treatment Segments Strengthens Role of Isoxazoline in Oral and Topical Formulations
    • OEM Innovation in Broad-Spectrum Molecules Enhances Efficacy Against Resistant Flea and Mite Populations
    • Growth in Preference for Long-Acting, Monthly Dosing Schedules Throws Spotlight on Systemic Isoxazoline Compounds
    • Increasing Regulatory Approvals for Next-Generation Isoxazolines Supports Rapid Geographic Market Entry
    • OEM Development of Palatable, Species-Specific Delivery Formats Enhances Compliance in Dogs and Cats
    • Rising Incidence of Vector-Borne Diseases in Animals Promotes Preventive Use of Isoxazoline Products
    • OEM Focus on Combination Therapies With Endoparasitic Coverage Expands Utility of Isoxazoline Molecules
    • Surge in E-Commerce Veterinary Drug Sales Supports Access to Isoxazoline-Based Products Without In-Clinic Visits
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Isoxazoline Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Isoxazoline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Fluralaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Fluralaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Fluralaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Afoxolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Afoxolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Afoxolaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Sarolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Sarolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Sarolaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lotilaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lotilaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Lotilaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Dog by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • JAPAN
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • CHINA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • EUROPE
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Isoxazoline by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • FRANCE
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • GERMANY
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Isoxazoline by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • INDIA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Isoxazoline by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Isoxazoline by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • AFRICA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030

IV. COMPETITION